Traws Pharma, Inc. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
EPS (Diluted)
$1
Book Value Per Share
$-0
Free Cash Flow Per Share
$-2
Cash Per Share
—
Revenue Per Share
$0
OCF Per Share
$-2
Return on Equity
-56.9%
Return on Assets
51.5%
Return on Invested Capital
87.5%
Current Ratio
0.72
Quick Ratio
0.72
Asset Turnover
0.16
R&D / Revenue
435.2%
SBC / Revenue
26.1%
Capex / Revenue
92.7%
Working Capital
$-3M
Net Current Asset Value
$-3M
Invested Capital
$-629K
OCF / Net Income
-1.98
FCF / Net Income
-2.26
Accruals Ratio (Sloan)
257.7%
Net Debt
—
Net Debt / EBITDA
—
Interest Coverage
—
Cash Coverage
—
Capex Coverage
-7.03
Tangible Common Equity
$-3M
TCE / Total Assets
-29.7%
NOPAT
$-14M
Cash ROIC
128.8%
WC / Revenue
-113.5%
Capex / D&A
42.38
Reinvestment Rate
-14.1%
Asset Growth vs Revenue Growth
-1192.0%
Revenue 5Y CAGR
64.6%
Book Value 5Y CAGR
—
Stock Price (FY-end)
$1
Market Cap
$9M
P/E Ratio
1.03
P/S Ratio
3.39
P/B Ratio
—
P/TB Ratio
—
Enterprise Value
$9M
EV / Sales
3.39
FCF Yield
-219.4%
Shareholder Yield
-7.7%
R&D Yield
128.3%
Capex Yield
27.3%
Shares Variation (YoY)
439.5%
Beta (5Y)
1.05
Cost of Equity
9.8%
52W High
$9
52W Low
$1
Trailing Return 1Y
-91.6%
Trailing Return 5Y
-99.4%
F-Score (Piotroski)
3.00
Z-Score (Altman)
-89.54
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.